Skip to main content
release_alert
Welcome to the new Scholars 3.0! Read about new features and let us know what you think.
cancel
Journal cover image

Infliximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients With Inflammatory Bowel Disease: A Prospective Cross-Sectional Observational Study.

Publication ,  Journal Article
Clarke, WT; Papamichael, K; Vande Casteele, N; Germansky, KA; Feuerstein, JD; Melmed, GY; Siegel, CA; Irving, PM; Cheifetz, AS
Published in: Inflamm Bowel Dis
October 18, 2019

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Inflamm Bowel Dis

DOI

EISSN

1536-4844

Publication Date

October 18, 2019

Volume

25

Issue

11

Start / End Page

e143 / e145

Location

England

Related Subject Headings

  • Prospective Studies
  • Middle Aged
  • Male
  • Infliximab
  • Inflammatory Bowel Diseases
  • Humans
  • Gastroenterology & Hepatology
  • Female
  • Enzyme-Linked Immunosorbent Assay
  • Electrophoretic Mobility Shift Assay
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Clarke, W. T., Papamichael, K., Vande Casteele, N., Germansky, K. A., Feuerstein, J. D., Melmed, G. Y., … Cheifetz, A. S. (2019). Infliximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients With Inflammatory Bowel Disease: A Prospective Cross-Sectional Observational Study. Inflamm Bowel Dis, 25(11), e143–e145. https://doi.org/10.1093/ibd/izz202
Clarke, William T., Konstantinos Papamichael, Niels Vande Casteele, Katharine A. Germansky, Joseph D. Feuerstein, Gil Y. Melmed, Corey A. Siegel, Peter M. Irving, and Adam S. Cheifetz. “Infliximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients With Inflammatory Bowel Disease: A Prospective Cross-Sectional Observational Study.Inflamm Bowel Dis 25, no. 11 (October 18, 2019): e143–45. https://doi.org/10.1093/ibd/izz202.
Clarke WT, Papamichael K, Vande Casteele N, Germansky KA, Feuerstein JD, Melmed GY, Siegel CA, Irving PM, Cheifetz AS. Infliximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients With Inflammatory Bowel Disease: A Prospective Cross-Sectional Observational Study. Inflamm Bowel Dis. 2019 Oct 18;25(11):e143–e145.
Journal cover image

Published In

Inflamm Bowel Dis

DOI

EISSN

1536-4844

Publication Date

October 18, 2019

Volume

25

Issue

11

Start / End Page

e143 / e145

Location

England

Related Subject Headings

  • Prospective Studies
  • Middle Aged
  • Male
  • Infliximab
  • Inflammatory Bowel Diseases
  • Humans
  • Gastroenterology & Hepatology
  • Female
  • Enzyme-Linked Immunosorbent Assay
  • Electrophoretic Mobility Shift Assay